At TFOS we are introducing regular post-IPO coverage: tracking how newly listed companies fare after their debut, beyond the first day's headline.
First up: Csquare (CSQR), Standard Nuclear (STDN) and Scribe Therapeutics (SCTX). Three July listings, three very different receptions from the market.
Why post-IPO coverage
A listing day tells you what bankers priced; the weeks after tell you what the market thinks. Following the same names through their first months shows which businesses convert attention into durable demand for the stock, and which fade once the allocation flippers are done.
The full company-by-company review is available to TFOS clients on the platform, and the discussion continues on our LinkedIn page.
Marketing communication, not independent investment research and not financial advice. Past performance is not a guide to future results. Turlov Family Office Securities (Pty) Ltd is an authorised FSP (52874).